Listed

Boston Scientific Corp

BSXNYSECIK 885725HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$5.44bnRevenue, Q2 FY2026, three months to 2026-06-30$5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 3, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$5.44bnRevenue, Q2 FY2026, three months to 2026-06-30$5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure+7.5% on a year earlier
  • Gross margin70.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $3.85bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure+3.1 pts on a year earlier
  • Operating margin21.6%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $1.18bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure+5.5 pts on a year earlier
  • Net margin16.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $905.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure+0.9 pts on a year earlier
  • Diluted EPS$0.61Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure+15.1% on a year earlier
  • Free cash flow$1.28bnFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.47bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0000885725-26-000053. Derived: 6-month figure less the 3-month figure.Capital expenditure: $195.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0000885725-26-000053. Derived: 6-month figure less the 3-month figure.Report this figure+13.3% on a year earlier

Last eight quarters

Full statements
Revenue$5.44bnGross margin 70.7%
Diluted EPS$0.61, Q2 FY2026
Free cash flow$1.28bn, Q2 FY2026
Boston Scientific Corp, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m4,209Revenue, Q3 FY2024, three months to 2024-09-30$4.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure4,561Revenue, Q4 FY2024, three months to 2024-12-31$4.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure4,663Revenue, Q1 FY2025, three months to 2025-03-31$4.66bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure5,061Revenue, Q2 FY2025, three months to 2025-06-30$5.06bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure5,065Revenue, Q3 FY2025, three months to 2025-09-30$5.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure5,286Revenue, Q4 FY2025, three months to 2025-12-31$5.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure5,203Revenue, Q1 FY2026, three months to 2026-03-31$5.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure5,442Revenue, Q2 FY2026, three months to 2026-06-30$5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure
Gross margin%68.8%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $2.90bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Revenue: $4.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure67.9%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $3.10bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $4.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure68.8%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $3.21bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Revenue: $4.66bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure67.7%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $3.42bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.06bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure69.9%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $3.54bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Revenue: $5.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure69.6%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $3.68bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $5.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure69.5%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $3.61bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Revenue: $5.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure70.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $3.85bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure
Operating margin%17.4%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $733.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Revenue: $4.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure14.8%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $675.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $4.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure19.8%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $921.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Revenue: $4.66bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure16.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $819.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.06bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure20.7%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $1.05bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Revenue: $5.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure15.6%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $825.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $5.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure21.2%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $1.10bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Revenue: $5.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure21.6%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $1.18bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure
Net margin%11.1%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $468.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Revenue: $4.21bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure12.3%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $562.0m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $4.56bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure14.4%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $672.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Revenue: $4.66bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure15.7%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $795.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.06bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure14.9%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $755.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Revenue: $5.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figure12.7%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $670.0m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Revenue: $5.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure25.7%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $1.34bn. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Revenue: $5.20bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure16.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $905.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Revenue: $5.44bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure
Diluted EPS$ per share0.32Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figurenot reported (Diluted EPS not reported)0.45Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure0.53Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure0.51Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0000885725-25-000050.Report this figurenot reported (Diluted EPS not reported)0.90Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure0.61Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0000885725-26-000053.Report this figure
Free cash flow$m823Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $1.00bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0000885725-25-000050. Derived: 9-month figure less the 6-month figure.Capital expenditure: $179.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0000885725-25-000050. Derived: 9-month figure less the 6-month figure.Report this figure1,179Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.46bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Capital expenditure: $277.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure354Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $541.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Capital expenditure: $187.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure1,129Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $1.29bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0000885725-26-000053. Derived: 6-month figure less the 3-month figure.Capital expenditure: $157.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0000885725-26-000053. Derived: 6-month figure less the 3-month figure.Report this figure1,162Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $1.34bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0000885725-25-000050. Derived: 9-month figure less the 6-month figure.Capital expenditure: $181.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0000885725-25-000050. Derived: 9-month figure less the 6-month figure.Report this figure1,013Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $1.36bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Capital expenditure: $351.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000885725-26-000010. Derived: 12-month figure less the 9-month figure.Report this figure171Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $348.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Capital expenditure: $177.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0000885725-26-000033.Report this figure1,279Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.47bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0000885725-26-000053. Derived: 6-month figure less the 3-month figure.Capital expenditure: $195.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0000885725-26-000053. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$20.07bnGross margin 69.0%
Diluted EPS$1.94, FY2025
Free cash flow$3.66bn, FY2025
Boston Scientific Corp, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$bn11.9Revenue, FY2021, twelve months to 2021-12-31$11.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000885725-24-000017.Report this figure12.7Revenue, FY2022, twelve months to 2022-12-31$12.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000885725-25-000011.Report this figure14.2Revenue, FY2023, twelve months to 2023-12-31$14.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure16.7Revenue, FY2024, twelve months to 2024-12-31$16.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure20.1Revenue, FY2025, twelve months to 2025-12-31$20.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure
Gross margin%68.8%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $8.18bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-20, accession 0000885725-24-000017.Revenue: $11.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000885725-24-000017.Report this figure68.8%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $8.73bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-18, accession 0000885725-25-000011.Revenue: $12.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000885725-25-000011.Report this figure69.5%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $9.90bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $14.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure68.6%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $11.49bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $16.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure69.0%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $13.85bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $20.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure
Operating margin%10.1%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $1.20bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-20, accession 0000885725-24-000017.Revenue: $11.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000885725-24-000017.Report this figure13.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $1.65bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-18, accession 0000885725-25-000011.Revenue: $12.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000885725-25-000011.Report this figure16.5%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $2.34bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $14.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure15.5%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $2.60bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $16.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure18.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $3.61bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $20.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure
Net margin%8.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $1.04bn. XBRL concept us-gaap:ProfitLoss. 10-K filed 2024-02-20, accession 0000885725-24-000017.Revenue: $11.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0000885725-24-000017.Report this figure5.5%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $698.0m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2025-02-18, accession 0000885725-25-000011.Revenue: $12.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0000885725-25-000011.Report this figure11.2%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $1.59bn. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $14.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure11.0%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $1.85bn. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $16.75bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure14.4%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $2.89bn. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-02-17, accession 0000885725-26-000010.Revenue: $20.07bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure
Diluted EPS$ per share0.69Diluted EPS, FY2021, twelve months to 2021-12-31$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-20, accession 0000885725-24-000017.Report this figure0.45Diluted EPS, FY2022, twelve months to 2022-12-31$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-18, accession 0000885725-25-000011.Report this figure1.07Diluted EPS, FY2023, twelve months to 2023-12-31$1.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure1.25Diluted EPS, FY2024, twelve months to 2024-12-31$1.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure1.94Diluted EPS, FY2025, twelve months to 2025-12-31$1.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure
Free cash flow$bn1.3Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $1.87bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-20, accession 0000885725-24-000017.Capital expenditure: $554.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-20, accession 0000885725-24-000017.Report this figure0.9Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $1.53bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-18, accession 0000885725-25-000011.Capital expenditure: $588.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-18, accession 0000885725-25-000011.Report this figure1.8Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $2.50bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000885725-26-000010.Capital expenditure: $711.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure2.6Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $3.44bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000885725-26-000010.Capital expenditure: $790.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure3.7Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $4.53bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0000885725-26-000010.Capital expenditure: $876.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0000885725-26-000010.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Boston Scientific Corp
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$5.53bn129,680,916Reduced−2,141,121
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$4.14bn97,087,553Added+675,985
STATE STREET CORP2026-06-30$2.99bn70,111,196Added+2,124,349
PRIMECAP MANAGEMENT CO/CA/2026-06-30$2.16bn50,520,914Added+17,991,140
FMR LLC2026-06-30$1.95bn45,702,845Reduced−28,523,550
MASSACHUSETTS FINANCIAL SERVICES CO /MA/2026-06-30$1.50bn24,859,191Added+13,862,619
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$1.42bn33,440,102Added+154,345
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$1.27bn29,792,794Reduced−3,417
D. E. Shaw & Co., Inc.2026-06-30$1.09bn25,457,409Added+1,145,057
JPMORGAN CHASE & CO2026-06-30$1.04bn23,907,838Reduced−9,442,319

Recent filings

All 3,572 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Boston Scientific Corp, recent filings
FiledFormWhat it isAccession number
2026-10-0706:11 ET8-K5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits0000885725-26-000064
2026-09-2306:01 ET8-K5.02 Departure or appointment of officers or directors0000885725-26-000061
2026-09-0806:15 ET8-K1.05 Material cybersecurity incident0000885725-26-000059
2026-08-2606:06 ET8-K8.01 Other events0000885725-26-000056
2026-08-0306:32 ET10-QQuarterly reportPeriod 2026-06-300000885725-26-000053
2026-07-2906:33 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000885725-26-000051
2026-07-2716:06 ET8-K2.05 Exit or disposal costs0000885725-26-000049
2026-05-1807:17 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0000885725-26-000042
2026-05-1807:15 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0000885725-26-000041
2026-05-0516:47 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0000885725-26-000036

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 17, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
885725
Tickers
BSX
Exchange
NYSE
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:35 ET. Listed shows no prices and gives no investment advice.